Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

被引：54
作者：
Boeckx, Carolien [1 ]
de Beeck, Ken Op [1 ,2 ,3 ]
Wouters, An [1 ]
Deschoolmeester, Vanessa [1 ]
Limame, Ridha [1 ]
Zwaenepoel, Karen [4 ]
Specenier, Pol [1 ,5 ]
Pauwels, Patrick [1 ,4 ]
Vermorken, Jan B. [1 ,5 ]
Peeters, Marc [1 ,5 ]
Van Camp, Guy [2 ,3 ]
Baay, Marc [1 ]
Lardon, Filip [1 ]
机构：
[1] Univ Antwerp, CORE Antwerp, Lab Canc Res & Clin Oncol, Antwerp, Belgium
[2] Univ Antwerp, Ctr Med Genet, Dept Biomed Sci, Antwerp, Belgium
[3] Univ Antwerp Hosp, Antwerp, Belgium
[4] Univ Antwerp Hosp, Dept Pathol, Antwerp, Belgium
[5] Univ Antwerp Hosp, Dept Med Oncol, Antwerp, Belgium
来源：
CANCER LETTERS | 2014年 / 354卷 / 02期
关键词：
Head and neck squamous cell carcinoma; Anti-EGFR therapy; Cetuximab resistance; Dual-specificity phosphatase 5 and 6; Aurora kinase B; Nano Pro 1000; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; APIGENIN INDUCES APOPTOSIS; NECK-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER; MESENCHYMAL TRANSITION; AURORA KINASES; MONOCLONAL-ANTIBODY;
D O I：
10.1016/j.canlet.2014.08.039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Unraveling the underlying mechanisms of cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is of major importance as many tumors remain non-responsive or become resistant. Our microarray results suggest that "resistant" cells still exhibit RAS-MAPK pathway signaling contributing to drug resistance, as witnessed by low expression of DUSP5 and DUSP6, negative regulators of ERK1/2, and increased expression of AURKB, a key regulator of mitosis. Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCc. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：365 / 377
页数：13
相关论文
共 72 条
  • [1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, Rafael G.
    Wolf, Michael
    Peeters, Marc
    Van Cutsem, Eric
    Siena, Salvatore
    Freeman, Daniel J.
    Juan, Todd
    Sikorski, Robert
    Suggs, Sid
    Radinsky, Robert
    Patterson, Scott D.
    Chang, David D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
  • [2] Ang KK, 2002, CANCER RES, V62, P7350
  • [3] Dynamic and label-free cell-based assays using the real-time cell electronic sensing system
    Atienza, Josephine M.
    Yu, Naichen
    Kirstein, Shelli L.
    Xi, Biao
    Wang, Xiaobo
    Xu, Xiao
    Abassi, Yama A.
    [J]. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2006, 4 (05) : 597 - 607
  • [4] The dual-specificity MAP kinase phosphatases: critical roles in development and cancer
    Bermudez, O.
    Pages, G.
    Gimond, C.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2010, 299 (02): : C189 - C202
  • [5] Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: Implications for anti-EGFR treatment response
    Boeckx C.
    Weyn C.
    Vanden Bempt I.
    Deschoolmeester V.
    Wouters A.
    Specenier P.
    Van Laer C.
    Van Den Weyngaert D.
    Kockx M.
    Vermorken J.B.
    Peeters M.
    Pauwels P.
    Lardon F.
    Baay M.
    [J]. BMC Research Notes, 7 (1)
  • [6] Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
    Boeckx, Carolien
    Baay, Marc
    Wouters, An
    Specenier, Pol
    Vermorken, Jan B.
    Peeters, Marc
    Lardon, Filip
    [J]. ONCOLOGIST, 2013, 18 (07) : 850 - 864
  • [7] Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells
    Bonet, Caroline
    Giuliano, Sandy
    Ohanna, Mickael
    Bille, Karine
    Allegra, Maryline
    Lacour, Jean-Philippe
    Bahadoran, Philippe
    Rocchi, Stephane
    Ballotti, Robert
    Bertolotto, Corine
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (35) : 29887 - 29898
  • [8] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    Bonner, JA
    Harari, PM
    Giralt, J
    Azarnia, N
    Shin, DM
    Cohen, RB
    Jones, CU
    Sur, R
    Raben, D
    Jassem, J
    Ove, R
    Kies, MS
    Baselga, J
    Youssoufian, H
    Amellal, N
    Rowinsky, EK
    Ang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) : 567 - 578
  • [9] Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma
    Bruckman, Karl C.
    Schoenleben, Frank
    Qiu, Wanglong
    Woo, Victoria L.
    Su, Gloria H.
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2010, 110 (05): : 632 - 637
  • [10] Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin
    Chan, Leong-Perng
    Chou, Tzung-Han
    Ding, Hsiou-Yu
    Chen, Pin-Ru
    Chiang, Feng-Yu
    Kuo, Po-Lin
    Liang, Chia-Hua
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2012, 1820 (07): : 1081 - 1091
12345678